Thalassemia and malignancies: Updates from the literature

Loading...
Thumbnail Image

Date

Journal Title

Journal ISSN

Volume Title

Publisher

John Wiley and Sons Inc

Abstract

Thalassemia management has undergone significant development with the advancement in iron chelation therapy, which has led to a prolonged life expectancy. This has been accompanied by the emergence of several new morbidities and chronic diseases, including cancer. Over the years, multiple cases of solid and hematologic malignancies in thalassemia patients have been reported in the literature, with no clear mechanism for the development of cancer in these patients despite a number of potential mechanisms. However, the results of many studies have been contradictory regarding the risk of development of malignancies in thalassemia. The present review aims to discuss the available data on cancer and thalassemia in the literature, with the latest updates regarding possible malignancy development mechanisms, risks, and the most commonly reported types. © 2023 The New York Academy of Sciences.

Description

Keywords

Malignancies, Non-transfusion-dependent thalassemia, Thalassemia, Transfusion-dependent thalassemia, Blood transfusion, Hematologic neoplasms, Humans, Iron chelating agents, Iron overload, Neoplasms, Iron chelating agent, Cancer prevention, Cytomegalovirus, Developing country, Disease predisposition, Hematologic malignancy, Hepatitis c virus, Iron chelation, Pathophysiology, Review, Tumor virus, Complication, Hematologic disease, Human, Neoplasm, Procedures

Citation

Endorsement

Review

Supplemented By

Referenced By